WallStSmart

BlackRock Science and Technology Trust II (BSTZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

BlackRock Science and Technology Trust II stock (BSTZ) is currently trading at $22.11. BlackRock Science and Technology Trust II PE ratio is 4.61. BlackRock Science and Technology Trust II PS ratio (Price-to-Sales) is 4.66. WallStSmart rates BSTZ as Sell.

  • BSTZ PE ratio analysis and historical PE chart
  • BSTZ PS ratio (Price-to-Sales) history and trend
  • BSTZ intrinsic value — DCF, Graham Number, EPV models
  • BSTZ stock price prediction 2025 2026 2027 2028 2029 2030
  • BSTZ fair value vs current price
  • BSTZ insider transactions and insider buying
  • Is BSTZ undervalued or overvalued?
  • BlackRock Science and Technology Trust II financial analysis — revenue, earnings, cash flow
  • BSTZ Piotroski F-Score and Altman Z-Score
  • BSTZ analyst price target and Smart Rating
BSTZ

BlackRock Science and Technology Trust II

NYSEFINANCIAL SERVICES
$22.11
$0.28 (1.28%)
52W$13.43
$23.18

📊 No data available

Try selecting a different time range

IV

BSTZ Intrinsic Value Analysis for Value Investors

Benjamin Graham Formula · BlackRock Science and Technology Trust II (BSTZ)

Margin of Safety
+26.4%
Undervalued
BSTZ Fair Value
$31.62
Graham Formula
Current Price
$22.11
$9.51 below fair value
Undervalued
Fair: $31.62
Overvalued
Price $22.11
Graham IV $31.62

BSTZ appears undervalued based on the Graham Formula, trading 26% below its estimated fair value of $31.62.

Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.

WallStSmart

Smart Analysis

BlackRock Science and Technology Trust II (BSTZ) · 4 metrics scored

Smart Score

26
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in price/book. Significant fundamental concerns warrant caution or avoidance.

BlackRock Science and Technology Trust II (BSTZ) Key Strengths (1)

Avg Score: 10.0/10
Price/BookValuation
0.8610/10

Trading below book value, meaning the market prices it less than net assets

Supporting Valuation Data

P/E Ratio
4.606
Undervalued
Trailing P/E
4.606
Undervalued

BlackRock Science and Technology Trust II (BSTZ) Areas to Watch (3)

Avg Score: 5.0/10
Price/SalesValuation
4.664/10

Premium valuation at 4.7x annual revenue

Market CapQuality
$1.47B5/10

Small-cap company with higher risk but more growth potential

Institutional Own.Quality
31.02%6/10

Moderate institutional interest at 31.02%

BlackRock Science and Technology Trust II (BSTZ) Detailed Analysis Report

Overall Assessment

This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 5.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.86) suggest the stock is attractively priced.

The Bear Case

The primary concerns are Price/Sales, Market Cap, Institutional Own.. Some valuation metrics including Price/Sales (4.66) suggest expensive pricing.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Price/Sales and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

BSTZ Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

BSTZ's Price-to-Sales ratio of 4.66x trades 38% below its historical average of 7.51x (29th percentile). The current valuation is 59% below its historical high of 11.45x set in Mar 2026, and 1% above its historical low of 4.6x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~11.4x as trailing revenue scaled faster than the stock price.

Compare BSTZ with Competitors

Top ASSET MANAGEMENT stocks by market cap

Compare any two stocks →

Insider Transactions

Loading insider activity...

About BlackRock Science and Technology Trust II(BSTZ)

Exchange

NYSE

Sector

FINANCIAL SERVICES

Industry

ASSET MANAGEMENT

Country

USA

BlackRock Science and Technology Trust II (BSTZ) is a strategically managed closed-end fund by BlackRock, focusing on high-growth investments within the science and technology sectors. With a keen emphasis on innovative companies that are at the forefront of technological advancements and scientific research, BSTZ aims to capitalize on the substantial growth potential in these dynamic fields. Backed by BlackRock's extensive market expertise, the trust seeks to provide attractive total returns through a combination of capital appreciation and income generation. This fund is particularly appealing to institutional investors looking to diversify their portfolios and gain exposure to long-term trends in technological innovation and healthcare developments.